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Previous studies suggest that sarcolemmal potassium currents play important roles in cardiac hypertrophy. IGF-1 contributes
to cardiac hypertrophy via activation of PI3K/Akt signaling. However, the relationships between IGF-1, PI3K/Akt signaling
and sarcolemmal potassium currents remain unknown. Therefore, we tested the hypothesis that IGF-1 and PI3K/Akt signaling,
independently, decrease sarcolemmal potassium currents in cardiac myocytes of neonatal rats. We compared the delayed outward
rectiﬁer (IK) and the inward rectiﬁer (IK) current densities resulting from IGF-1 treatments to those resulting from simulation
of PI3K/Akt signaling using adenoviral (Ad) BD110 and wild-type Akt and to those resulting from inhibition of PI3K signaling
by LY294002. Ad.BD110 and Ad.Akt decreased IK and these decrements were attenuated by LY 294002. The IGF-1 treatments
decreased both IK and IK1 but only the IK decrement was attenuated by LY294002. These ﬁndings demonstrate that IGF-1
may contribute to cardiac hypertrophy by PI3K/Akt signal transduction mechanisms in neonatal rat cardiomyocytes. Failure of
LY294002toeﬀectivelyantagonizeIGF-1induceddecrementsinIK1 suggeststhatasignalpathwayadjuncttoPI3K/Aktcontributes
to IGF-1 protection against arrhythmogenesis in these myocytes. Our ﬁndings imply that sarcolemmal outward and inward
rectiﬁer potassium channels are substrates for IGF-1/PI3K/Akt signal transduction molecules.
1.Introduction
An intricate interconnected network of intracellular sig-
naling molecules participate in regulating the electrical
activity, size, and contractility of cardiac myocytes [1, 2].
Dysregulation of sarcolemmal potassium currents is known
to contribute to ventricular hypertrophy, arrhythmogenesis,
heart failure, and sudden death in adults [3]. Insulin-
like growth factor-1 (IGF-1) is an antiarrhythmogenic and
antiapoptotic modulator of cardiac myocyte hypertrophy
[4]. IGF-1 is thought to contribute to cardiac myocyte
hypertrophy and, at the same time protect cardiac myocytes
fromarrhythmogenesisandapoptosisbyactivatingthephos-
phatidyl inositol-3 kinase (PI3K/Akt) cell survival intracellu-
lar signaling [4, 5]. However, the role of IGF-1 and PI3K/Akt
signaling in mediating the sarcolemmal potassium current
density remains unknown. The present study was, therefore,
designed to test the hypothesis that IGF-1 and PI3K/Akt
signaling independently modulate sarcolemmal IK and IK1 in
cardiac myocytes.
2.MaterialsandMethods
2.1.AnimalPreparation. Conformity statement:asdiscussed
in the following respective sections, all the procedures
conform to the Guide for the Care and Use of Laboratory
Animals published by the US National Institutes of Health
(NIH) publication number 85–23, revised 1996. Pregnant
female Sprague-Dawley rats of 200–250g body weight were
purchased from Charles Rivers (MA). The rats were allowed
to recover and acquaint with their new environment upon
arrival to the animal house of the Howard University College
of Medicine for 3 days pre-partum. The pups were kept
with the dams under secure, clean and controlled room
temperature (70◦F–74◦F) with a 6:00h to 18:00h light cycle
and the mothers were fed food and water ad libitum.2 International Journal of Cell Biology
2.2. Recombinant Adenoviral Vectors. Recombinant adenovi-
ralvectorswerepreparedaspreviouslydescribed[6,7]byco-
transfection of a shuttle vector carrying the cDNA of interest
with a source of viral backbone DNA (either pAd.Track and
pAd.EASY1).
2.3. Preparation of Neonatal Rat Cardiac Myocytes. Neonatal
cardiomyocytes preparation followed the Neonatal Car-
diomyocyte Isolation System Kit (Worthington Biochemical
Corporation). Freshly isolated cells were transferred to a
water-jacketed CO2 incubator for at least 24h before use.
Cells were placed in a perfusion bath on the stage of an
inverted microscope and superfused with the appropriate
recording solution at a rate of 1-2mL/min. Isolated cultured
cells were incubated with IGF-1 or the LY294002 inhibitor
of PI3K signaling, with normal culture media serving as the
control. Cells were also transfected with adenovirus carrying
the constitutive BD110 activator of PI3K or carrying the
wild-type Akt mutant before use, with adenoviral enhanced
green ﬂuorescent protein (Ad.EGFP) serving as the control.
2.4. Electrophysiological Eﬀects on IK and IK1. Ventricular
myocytes were placed in a culture dish with an extracellular
buﬀer containing (mM): 5 KCl, 1 MgCl2, 140 NaCl, 10
HEPES, 10 D-glucose, 1 CaCl2, 0.2 CdCl2, to which we
added 0.1μM IGF-1 [8] and/or 3μM LY 294002 [8], Ad.Akt
1011 pfu/mL (10, 11] and/or Ad.BD110 1011 pfu/mL [6, 7],
and pH at 7.4. The voltage dependency of IK activation was
studied by obtaining data for the respective current-voltage
(I-V) relationships. To that end, 350ms step voltages in
10mV increments between −40mV and +30mV were
applied from a holding potential of −80mV, but with a
200ms prepulse to −40mV. For IK1, 350ms step voltages in
10mV increments between −140mV and −90mV were
applied from a holding potential of −80mV. Steady-state
currents, measured at the end of each current response, were
plotted as a function of the command potential. The actions
of IGF-1, in the presence and absence of the constitutive Ad.
BD110 or wild-type Ad.Akt activators and in the presence
and absence of the LY294002 inhibitor of PI3K signaling,
were analyzed for their eﬀects on the current-voltage (I-V)
relationship. LY 294002, an inhibitor of PI3K, was purchased
from Cell Signaling Technology (MA). Sarcolemmal potas-
sium currents (IK and IK1) were expressed in current density,
pA/pF. Ad.EGFP data served as the control for evaluating the
eﬀects of transfections.
2.5. Statistical Analysis. The eﬀects of treatments of neonatal
cardiomyocytes with IGF-1 alone and in combination with
theconstitutiveAd.BD110orwild-typeAd.Aktactivevectors
or with the LY294002 inhibitor of PI3K signaling on the
pA/pF values at each membrane potential were compared by
repeated measures ANOVA with signiﬁcance set at P<0.05.
3. Results
3.1. Eﬀects of IGF-1 on IK. To evaluate the eﬀects of IGF-
1/PI3K/Akt signaling on IK activity, neonatal cardiomyocytes
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Figure 1: Eﬀects of IGF-1, Ad.Akt and Ad.BD110 treatments on
the IK-voltage relationship for normal neonatal rat cardiomyocytes.
Data are presented as average current density (pA/pF) ± standard
error. ∗Signiﬁcant diﬀerence at P<0.05 for control and Ad.EGFP
versus IGF-1, Ad.Akt, and Ad.BD110 treatments.
were pharmacologically treated with the speciﬁc PI3K sig-
naling inhibitor LY294002 or transfected for at least 24h
with adenovirus carrying the constitutive PI3K activator
Ad.BD110 or the wild-type Akt activator Ad.Akt. Figure 1
shows that treatment of cultured neonatal cardiomyocytes
with IGF-1 (2.6 ± 0.4pA/pF, 39.53 ± 2%; n = 8,
P<0.05), transfection with Ad.BD110 (2.5 ± 0.5pA/pF,
47.91 ± 1.5%; n = 7, P<0.05) or transfection with Ad.Akt
(2.4 ± 0.3pA/pF, 50.00 ± 1.4%; n = 8, P<0.05) decreased
IK density by a similar magnitude when compared to the
normal (4.3 ± 0.8pA/pF; n = 10) and the Ad.EGFP (4.8 ±
0.7pA/pF; n = 8) control values. Recordings representative
of the current responses are shown in Figure 2. Figure 3
also demonstrates that application of the PI3K inhibitor
LY294002 attenuated the IGF-1, Ad.Akt, and Ad.BD110
eﬀects signiﬁcantly (4.5 ± 0.5pA/pF; 4.8 ± 0.4pA/pF; 4.2 ±
0.2pA/pF, respectively, P<0.05). Recordings representative
of the current responses for the LY294002 combination
treatments are shown in Figure 4.
3.2. Eﬀects of IGF-1 on IK1. To determine whether the
electrophysiological activity of IK1 is regulated by IGF-
1/PI3K/Akt pathway, the cardiomyocytes were treated with
IGF-1 or transfected with Ad.Akt. Figure 5 shows that IK1
c u r r e n td e n s i t yw a sd e c r e a s e da f t e rt r e a t m e n t sw i t hI G F - 1
by 23.46 ± 3.8% (−7.5 ± 0.9pA/pF; n = 8, P<0.05) or,
after transfection with Ad.Akt, by 38.54 ± 1.8% (−5.9 ±
0.9pA/pF; n = 6, P<0.05), compared to the normal control
(−9.8 ± 0.9pA/pF; n = 10) and to the Ad.EGFP control
values (−9.7 ± 0.8pA/pF; n = 8). Recordings representative
of the current responses are shown in Figure 6. Figure 7
shows that application of the PI3K inhibitor LY294002 failed
to alter both the IGF-1 and the Ad.Akt eﬀects on IK1 density.
Recordings representative of the current responses for the
LY294002 combination treatments are shown in Figure 8.International Journal of Cell Biology 3
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Figure 2: Recording representative of the time courses for the
eﬀects of IGF-1, Ad.Akt, and Ad.BD110 treatments on IK of normal
neonatal rat cardiomyocytes at the clamp voltage of +30mV.
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Figure 3: Eﬀects of IGF-1, Ad.Akt, and Ad.BD110 in combination
withLY294002treatmentsontheIK-voltagerelationshipfornormal
neonatal rat cardiomyocytes. Data are presented as average current
density (pA/pF) ± standard error.
4. Discussion
During ventricular hypertrophy, changes in ion channel
activity are mediated by intracellular signal transduction
mechanisms connected to the addition or subtraction of the
f e t a lg e n ep r o g r a m[ 9]. IGF-1 is known to activate PI3K
and its downstream target Akt, a serine threonine kinase,
also known as protein kinase [10–12]. IGF-1 binding to its
receptor with downstream activation of PI3K and Akt has
been demonstrated [13, 14]. IGF-1 is known to play a
major role in cellular proliferation and diﬀerentiation [15–
17] .T r e a t m e n to fc u l t u r e dn e w b o r nr a tc a r d i a cm y o c y t e s
with IGF-1 is reported to activate speciﬁc genes that
accompany electrophysiological changes [18]a n dI G F - 1
mRNA and protein to increase in parallel with alterations in
sarcolemmal ion currents [19]. Furthermore, overexpression
of Akt appears to induce changes in the electrophysiological
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Figure 4: Recording representative of the time courses for the
eﬀects of IGF-1, Ad.Akt, and Ad.BD110 in combination with LY
294002 treatments on IK of normal neonatal rat cardiomyocytes at
the clamp voltage of +30mV. Current expressed as pA.
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Figure 5: Eﬀects of IGF-1 and Ad.Akt treatments on the IK1-
voltage relationship for normal neonatal rat cardiomyocytes. Data
are presented as average current density (pA/pF) ± standard error.
∗#Signﬁcant diﬀerences at P<0.05 for control and Ad.EGFP versus
IGF-1 and Ad.Akt treatments.
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Figure 6: Recording representative of the time courses for the
eﬀectsofIGF-1andAd.AkttreatmentsinIK1 ofnormalneonatalrat
cardiomyocytes at the clamp voltage of −120mV.4 International Journal of Cell Biology
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Figure 7: Eﬀects of IGF-1 and Ad.Akt in combination with
LY294002 treatments on the IK1-voltage relationship for normal
neonatal rat cardiomyocytes. Data are presented as average current
density (pA/pF) ± standard error. ∗#Signiﬁcant diﬀerences at
P<0.05 for control and Ad.EGFP versus IGF-1 and Ad.Akt in
combination with LY294002 treatments.
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Figure 8: Recording representative of the time courses for the
eﬀects of IGF-1 and Ad.Akt in combination with LY294002
treatments on IK1 of normal neonatal rat cardiomyocytes at the
clamp voltage of −120mV. Current expressed as pA.
properties of the hearts of transgenic mice [20, 21]. These
ﬁndings suggest important roles for IGF-1, as well as
signiﬁcant gaps in knowledge concerning IGF-1 regulation
of sarcolemmal potassium channels by the PI3K/Akt cell
survival signal transduction pathway.
In the present study, we characterized the alterations of
potassium channel current density (IK and IK1) associated
with treatments of cultured neonatal rat cardiomyocytes
with IGF-1 alone and in combination with two activators
(Ad.BD110, Ad.Akt) and one inhibitor of the PI3K/Akt sig-
naling pathway. We demonstrated signiﬁcant decrements in
IK and IK1 current density by IGF-1. The eﬀects of IGF-1 on
IK seemed to be mediated, largely, by PI3K/Akt signaling.
Although IK1 was found to be sensitive to treatment with
IGF-1 and Ad.Akt, LY294002 had no signiﬁcant eﬀect on the
IGF-1-induced decrement in IK1 density. This ﬁnding sug-
gests that IGF-1 might modulate IK1 by another mechanism
cross-talking downstream from PI3K/Akt signaling and that
the inward rectiﬁer channel (Kir) may not be a direct
substrate for the PI3K/Akt signaling molecules.
The stimulators of intracellular signal transduction
molecules Ad.BD110, a constitutively active PI3K and
Ad.Akt, wild-type Akt, decreased IK density. The wild-type
Ad.Akt also decreased IK1 density. The Akt simulator Ad.Akt
also decreased IK1 density. However, the PI3K inhibitor
LY294002 eﬀectively antagonized the eﬀects of IGF-1,
Ad.BD110, and Ad.Akt on IK density but failed to antagonize
theeﬀectsofIGF-1andAd.AktonIK1 density.Alimitationof
this study is that the eﬀects of Ad.BD110 on IK1 density
were not determined. Nevertheless, these results imply that
both PI3K and Akt signaling pathway molecules play roles in
the decrement in IK density associated with IGF-1, an eﬀect
known to increase the duration of cardiac myocyte action
potentials. However, although Akt signaling seems to play a
role in the decrement in IK1 density associated with IGF-1,
this eﬀect appears to be independent of PI3K activity.
The IGF-1/PI3K/Akt signaling pathway is the best char-
acterized example of intracellular signal transduction con-
tributing to physiological and pathological cardiac hypertro-
phies.IGF-1/PI3K/Aktsignalingmoleculesarereportedtobe
critical for exercise-induced cardiac hypertrophy [5, 13], in
concert with AMP-activated kinase [22]. The eﬀects of IGF-
1/PI3K/AktsignalingonIK andIK1 inexercise-hypertrophied
cardiomyocytes have not been demonstrated. It is tempting
to speculate that IGF-1/PI3K/Akt signaling mediates physio-
logical growth and hypertrophy and antagonizes pathologi-
cal hypertrophy [13]. However, the mechanisms underlying
pathological hypertrophy appear to be more complex. We
have demonstrated that IGF-1/PI3K/Akt signaling also plays
a role in eccentrically hypertrophied adult rat cardiomy-
ocytes, decreasing the current densities of both IK and IK1
[8, 23]. IGF-1 appears to upregulate the transient outward
potassium current associated with the early repolarization of
phase1oftheventricularmyocyteactionpotentialinnormal
neonatal rat cardiomyocytes [24]. Although Ito initiates
repolarization, the delay in completing repolarization and
prolongingdepolarizationismainlyafunctionofthephase3
outwardly rectifying current, IK. We previously reported that
downregulation of ATP-sensitive potassium channel current
(IKATP)isacharacteristicofvolume-overloaded,eccentrically
hypertrophied adult rat cardiac myocytes which is thought
to increase the duration of ventricular action potentials and
increase inotropy of the myocytes [25]. The IGF-1 induced
decrement in IK described in the present study might also
contribute to prolonging ventricular action potentials. This
IGF-1 induced decrement in IK was simulated by activating
the PI3K/Akt pathway using both Ad.BD110 and Ad.Akt and
has been shown to be sensitive to inhibition by the PI3K
inhibitor LY294002. These ﬁndings suggest that PI3K/Akt
signaling molecules could serve as substrates for inhibiting
cardiomyocyte hypertrophy in neonatal cardiac myocytes.
IK1 is the inwardly rectifying potassium current responsible
for restoring the resting membrane potential and excitabilityInternational Journal of Cell Biology 5
of ventricular myocytes. Upregulation of IK1 is reported
to be a signiﬁcant contributor to the cardiac arrhythmias
associated with hypertrophy of cardiac myocytes [26, 27].
TheIGF-1-induceddecrementinIK1,simulatedbyactivating
the PI3K/Akt signaling pathway using Ad.Akt and insensitive
to the PI3K inhibitor LY294002, is, therefore, likely to be
dependent on the signaling molecules associated with an
alternate or adjunctive signaling pathway such as AMP-
activated kinase shown to play a role in cardiac myocyte
hypertrophy [22]. The IGF-1-induced decrement in IK1,b y
virtue of the role of IK1 on resting membrane excitability, is
likelytoprotectagainstthearrhythmogenesisassociatedwith
cardiac myocyte hypertrophy [5]. Decreasing the inward
potassium resting potential stabilization current may, there-
fore,increasethethresholdforventriculararrhythmogenesis,
and the Kir channels in neonatal cardiac myocytes might,
therefore, function as substrates for treatments to inhibit
the predictable, potentially fatal ventricular arrhythmias
associated with adult cardiac hypertrophy [28–31]a n dw i t h
hypertrophy associated with neonatal cardiomyopathy [32].
We did not look for or observe any signiﬁcant changes
in the size of the neonatal cardiac myocytes that we studied.
T h e s en o r m a ln e o n a t a lc a r d i a cm y o c y t e sw e r eu s e da sa
model to determine whether the decrements in IK and IK1
density, whichwepreviouslyobserved in eccentricallyhyper-
trophied adult rat cardiac myocytes and not in normal adult
rat cardiac myocytes exposed to IGF-1 [8, 23]w e r ee ﬀects
inherent or speciﬁc to such hypertrophied cardiac myocytes.
The results of the present study, demonstrating decreased
IK and IK1 density in normal neonatal cardiac myocytes,
suggest that similar eﬀects could be elicited from not only
eccentricallyhypertophiedadultratcardiomyocytes,butalso
from normal neonatal rat cardiomyocytes treated with, or
exposed to, IGF-1.
5. Conclusions
The present study demonstrates that stimulation of the
IGF-1/PI3K/Akt cell survival signaling pathway decreases
activities of the sarcolemmal IK outward and the IK1
inward rectiﬁer currents of neonatal cardiac myocytes. These
results in normal neonatal rat cardiac myocytes are in
agreement with our previous reports in volume-overloaded,
eccentrically hypertrophied adult rat cardiac myocytes. Our
ﬁndings imply that sarcolemmal outward and inward rec-
tiﬁer potassium channels are substrates for IGF-1/PI3K/Akt
signal transduction molecules. Comparisons of the eﬀects of
cellular signal transduction molecules on normal and hyper-
trophied cardiomyocytes may be useful experimental models
for elucidating the sarcolemmal ion channel substrates and
regulatory mechanisms underlying both neonatal and adult
cardiac cardiomyopathies.
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